HC Wainwright Cuts Earnings Estimates for Hemab Therapeutics

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) – Equities research analysts at HC Wainwright reduced their FY2027 earnings estimates for shares of Hemab Therapeutics in a research note issued to investors on Monday, July 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($2.81) per share for the year, down from their previous forecast of ($2.69). HC Wainwright has a “Buy” rating and a $52.00 price objective on the stock. HC Wainwright also issued estimates for Hemab Therapeutics’ FY2028 earnings at ($3.63) EPS, FY2029 earnings at ($3.89) EPS and FY2030 earnings at ($2.44) EPS.

Several other research firms have also recently commented on COAG. Evercore began coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price for the company. The Goldman Sachs Group assumed coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target on the stock. Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Jefferies Financial Group boosted their price objective on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a “buy” rating in a report on Monday. Finally, Wedbush restated an “outperform” rating and issued a $55.00 price objective (up from $42.00) on shares of Hemab Therapeutics in a research report on Monday. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.00.

Hemab Therapeutics Stock Up 2.8%

Shares of COAG stock opened at $44.53 on Wednesday. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $45.27. The stock has a market capitalization of $2.08 billion and a P/E ratio of -1.86. The stock has a fifty day simple moving average of $29.73.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Buying and Selling

In other news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the stock in a transaction on Monday, May 4th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the transaction, the director directly owned 6,149,096 shares of the company’s stock, valued at approximately $110,683,728. This trade represents a 77.00% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Insiders acquired a total of 2,970,541 shares of company stock valued at $55,459,603 over the last quarter.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.